Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
5
6
2020
medline:
11
11
2020
entrez:
5
6
2020
Statut:
ppublish
Résumé
The novel coronavirus severe acute respiratory syndrome coronavirus 2 [coronavirus disease 2019 (COVID-19)] poses unique challenges for immunosuppressed patients. Solid organ transplant (SOT) recipients comprise a large proportion of this group, yet there is limited knowledge about the presentation, clinical course, and immunosuppression management of this novel infection among heart, lung, liver, pancreas, and kidney transplant recipients. We present 21 SOT recipients diagnosed with COVID-19 between January 1, 2020 and April 22, 2020 at a US high-volume transplant center. Diagnostic workup, clinical course, immunosuppression/antiviral management, and immediate outcomes are described. Twenty-one (15.9%) of 132 symptomatic patients tested were positive. Mean age at diagnosis was 54.8 ± 10.9 y. Median time from transplant was 5.58 y (interquartile range 2.25, 7.33). Median follow-up was 18 d (interquartile range 13, 30). Fourteen patients required inpatient management, with 7 (50%) placed in the intensive care unit (ICU). All transplant types were represented. Nearly 43% exhibited GI symptoms. Over half (56.2%) presented with elevated serum creatinine suggestive of acute kidney injury. The majority of patients (5/7) with concomitant infections at baseline required the ICU. Eighty percent received hydroxychloroquine ± azithromycin. Ten received toclizumab and/or ribavirin; 1 received remdesivir. Antimetabolites ± calcineurin inhibitors were held or reduced. Over half of hospitalized patients (8/14) were discharged home. Only 1 mortality (4.8%) to date, in a critically ill heart/kidney patient who had been in the ICU before diagnosis. COVID-19 positive SOT at our institution had favorable short-term outcomes. Those with concomitant infections had more severe illness. More data will be available to evaluate long-term outcomes and disease impact on graft function.
Sections du résumé
BACKGROUND
The novel coronavirus severe acute respiratory syndrome coronavirus 2 [coronavirus disease 2019 (COVID-19)] poses unique challenges for immunosuppressed patients. Solid organ transplant (SOT) recipients comprise a large proportion of this group, yet there is limited knowledge about the presentation, clinical course, and immunosuppression management of this novel infection among heart, lung, liver, pancreas, and kidney transplant recipients.
METHODS
We present 21 SOT recipients diagnosed with COVID-19 between January 1, 2020 and April 22, 2020 at a US high-volume transplant center. Diagnostic workup, clinical course, immunosuppression/antiviral management, and immediate outcomes are described.
RESULTS
Twenty-one (15.9%) of 132 symptomatic patients tested were positive. Mean age at diagnosis was 54.8 ± 10.9 y. Median time from transplant was 5.58 y (interquartile range 2.25, 7.33). Median follow-up was 18 d (interquartile range 13, 30). Fourteen patients required inpatient management, with 7 (50%) placed in the intensive care unit (ICU). All transplant types were represented. Nearly 43% exhibited GI symptoms. Over half (56.2%) presented with elevated serum creatinine suggestive of acute kidney injury. The majority of patients (5/7) with concomitant infections at baseline required the ICU. Eighty percent received hydroxychloroquine ± azithromycin. Ten received toclizumab and/or ribavirin; 1 received remdesivir. Antimetabolites ± calcineurin inhibitors were held or reduced. Over half of hospitalized patients (8/14) were discharged home. Only 1 mortality (4.8%) to date, in a critically ill heart/kidney patient who had been in the ICU before diagnosis.
CONCLUSIONS
COVID-19 positive SOT at our institution had favorable short-term outcomes. Those with concomitant infections had more severe illness. More data will be available to evaluate long-term outcomes and disease impact on graft function.
Identifiants
pubmed: 32496357
doi: 10.1097/TP.0000000000003339
pmc: PMC7302089
pii: 00007890-202011000-00002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2208-2214Références
World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 72. 2020; 72
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–513
Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese Med J. 2020; 133:1032–1038. doi:10.1097/CM9.0000000000000775
doi: 10.1097/CM9.0000000000000775
Gainer SM, Patel SJ, Seethamraju H, et al. Increased mortality of solid organ transplant recipients with H1N1 infection: a single center experience. Clin Transplant. 2012; 26:229–237. doi:10.1111/j.1399-0012.2011.01443.x
doi: 10.1111/j.1399-0012.2011.01443.x
Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis. 2020; 20:e102–e107. doi:10.1016/S1473-3099(20)30129-8
doi: 10.1016/S1473-3099(20)30129-8
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368:473–474. doi:10.1126/science.abb8925
doi: 10.1126/science.abb8925
Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020; 95:304–307. doi:10.1016/j.ijid.2020.04.061
doi: 10.1016/j.ijid.2020.04.061
Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 20202374; 382(24):2372. doi:10.1056/NEJMc2010419
doi: 10.1056/NEJMc2010419
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323:1061–1069. doi:10.1001/jama.2020.1585
doi: 10.1001/jama.2020.1585
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382(24):2327–2336. doi:10.1056/NEJMoa2007016
doi: 10.1056/NEJMoa2007016
Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020; 97:1076–1082. doi:10.1016/j.kint.2020.03.018
doi: 10.1016/j.kint.2020.03.018
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:343–346. doi:10.15585/mmwr.mm6912e2
doi: 10.15585/mmwr.mm6912e2
Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol. 2020; 31:1150–1156. doi:10.1681/asn.2020030375
doi: 10.1681/asn.2020030375
Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020; Apr 24. 10.1111. doi:10.1111/ajt.15941
doi: 10.1111/ajt.15941
Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Eng J Med. 2020; 382:2475–2477. doi:10.1056/NEJMc2011117
doi: 10.1056/NEJMc2011117
World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200423-sitrep-94-covid-19.pdf?sfvrsn=b8304bf0_4. Accessed April 23, 2020
Harris County Public Health. Harris County/Houston COVID-19 cases. Available at http://publichealth.harriscountytx.gov/Resources/2019-Novel-Coronavirus. Accessed April 27, 2020
Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. Morb Mortal Wkly Rep. 2020; 69:458–464. doi:10.15585/mmwr.mm6915e3
doi: 10.15585/mmwr.mm6915e3
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8:475–481. doi:10.1016/S2213-2600(20)30079-5
doi: 10.1016/S2213-2600(20)30079-5
Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020; 20:1859–1863. doi:10.1111/ajt.15869
doi: 10.1111/ajt.15869
Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013; 5:1250–1260. doi:10.3390/v5051250
doi: 10.3390/v5051250
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39:405–407. doi:10.1016/j.healun.2020.03.012
doi: 10.1016/j.healun.2020.03.012